Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 366

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 366
---
$1.82 per Common Share. The terms and conditions of the Transaction are more fully set forth in the Agreement, the Plan of Arrangement and the CVR Agreement

| BOSTON | CHARLOTTE | MIAMI | NASHVILLE | NEW YORK | SAN FRANCISCO |     | LEERINK.COM |

B-1

The Board of Directors

Repare Therapeutics Inc.

November 14, 2025

Page
2

We have been engaged by the Company
to act as its financial advisor in connection with the Transaction and we will receive a fee from the Company for providing such services, a portion of which is payable upon delivery of this opinion and the remaining (and principal) portion of which
is contingent upon consummation of the Transaction. In addition, the Company has agreed to reimburse certain of our expenses arising, and indemnify us against certain liabilities that may arise, out of our engagement.

Leerink Partners LLC is a full-service securities firm engaged in securities trading and brokerage activities as well as investment banking and financial
advisory services. Since October 2025, we have served as sales agent under Guarantor’s at-the-market sales agreement, and have received fees for such services. Except for the foregoing, during the past two years we have not provided investment
banking services to the Company, Parent or their respective affiliates. In the ordinary course of business, we may in the future provide investment banking services to the Company, Parent, Guarantor or their respective affiliates and would expect to
receive customary fees for the rendering of such services. In the ordinary course of our trading and brokerage activities, we have in the past held and may in the future hold positions, for our own account or the accounts of our customers, in
equity, debt or other securities of the Company, Parent, Guarantor or their respective affiliates.

Consistent with applicable legal and regulatory
requirements, we have adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or
publish research reports with respect to the Company, Parent, Guarantor, and the Transaction and other participants in the Transaction that differ from the views of our investment banking personnel.

In connection with this opinion, we have reviewed, among other things: (i) the proposed execution version of the Agreement, as provided to us by the
Company on November 14, 2025; (ii) the proposed execution version of